Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N - tert -butylguanidine- or N - tert -butyl- N ′- methylguanidine-bridged nucleic acids
Nucleic Acids Research · 25.08.2023 · 51 (15) · 7749-7761
DOI: 10.1093/nar/gkad608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 18.07.2023. Verfasst von Takao Yamaguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Methylguanidine, Oligonucleotides, Guanidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Institute for Open and Transdisciplinary Research Initiatives.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) are becoming a promising class of drugs for treating various diseases. Over the past few decades, many modified nucleic acids have been developed for application to ASOs, aiming to enhance their duplex-forming ability toward cognate mRNA and improve their stability against enzymatic degradations. Modulating the sugar conformation of nucleic acids by substituting an electron-withdrawing group at the 2′-position or incorporating a 2′,4′-bridging structure is a common approach for enhancing duplex-forming ability. Here, we report on incorporating an N-tert-butylguanidinium group at the 2′,4′-bridging structure, which greatly enhances duplex-forming ability because of its interactions with the minor groove. Our results indicated that hydrophobic substituents fitting the grooves of duplexes also have great potential to increase duplex-forming ability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.
- National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
- Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, 1-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
ORCID-Profile: Takao Yamaguchi, Satoshi Obika
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Institute for Open and Transdisciplinary Research Initiatives
- Hoansha Foundation
- Osaka University
Zitieren
APA
Yamaguchi, T., Horie, N., Aoyama, H., Kumagai, S., & Obika, S. (2023). Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N - tert -butylguanidine- or N - tert -butyl- N ′- methylguanidine-bridged nucleic acids. Nucleic Acids Research, 51(15), 7749-7761. https://doi.org/10.1093/nar/gkad608
Vancouver
Yamaguchi T, Horie N, Aoyama H, Kumagai S, Obika S. Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N - tert -butylguanidine- or N - tert -butyl- N ′- methylguanidine-bridged nucleic acids. Nucleic Acids Research. 2023;51(15):7749-7761. doi:10.1093/nar/gkad608
BibTeX
@article{Yamaguchi2023,
author = {Yamaguchi, Takao and Horie, Naohiro and Aoyama, Hiroshi and Kumagai, Shinji and Obika, Satoshi},
title = {Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N - tert -butylguanidine- or N - tert -butyl- N ′- methylguanidine-bridged nucleic acids},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {15},
pages = {7749--7761},
doi = {10.1093/nar/gkad608}
}
EUVIMED